New-Onset T1D Trials
Many immunotherapy clinical trials target individuals who have recently been diagnosed with type 1 diabetes, with goals to preserve their beta cell function and prevent disease progression. Find the list of clinical trials offered in the area along with contact information and links to more information.
COUR CNP-103-CL-201
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
Who Can Participate
- Between the ages of 12-35 years
- Diagnosed with Stage 3 type 1 diabetes within the past 180 days (based on ADA guidelines)
Joslin Diabetes Center, Boston, MA
UBMD Pediatric, Buffalo, NY
Columbia University Irving Medical Center, New York, NY
Mainstreet Health, Syosset, NY
Multiple Other Sites
GNTI-122 POLARIS
A Study of GNTI-122 in Adults Recently Diagnosed With T1D (POLARIS)
Who Can Participate
- Between the ages of 18 and 45 years
- Diagnosed with Stage 3 Type 1 Diabetes within 120 days
Joslin Diabetes Center, Boston, MA
Icahn School of Medicine at Mount Sinai, New York, NY
Multiple Other Sites
GentiBio HLA
HLA Demographics Study in Adults With Type 1 Diabetes
Who Can Participate
- Between the ages of 2-45 years
- Within 120 days of T1D diagnosis
Joslin Diabetes Center, Boston MA
Icahn School of Medicine at Mount Sinai, New York, NY
Multiple Other Sites
FABULINUS
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy
Who Can Participate
- Between the ages of 12-21 years
- Initiated exogenous insulin replacement therapy not longer than 90 days prior to screening visit at which random C-peptide will be assessed (V1)
Joslin Diabetes Center, Boston, MA
University of Buffalo, Buffalo, NY
Multiple Other Sites
DIAGNODE-3
A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes
Who Can Participate
- Between the ages of 12-29 years
- Within 6 months of T1D diagnosis
Joslin Diabetes Center, Boston, MA
Hassenfeld Children's Hospital at NYU Langone Health, Pediatric Diabetes Center, New York, NY
Multiple Other Sites
T1D RELAY
Rituximab-pvvr / Abatacept Newly Diagnosed Study
Joslin Diabetes Center, Boston, MA
Naomi Berrie Diabetes Center, New York, NY
Yale University, New Haven, CT
JAKPOT T1D
JAK Inhibitors Newly Diagnosed Study
Joslin Diabetes Center, Boston, MA
Naomi Berrie Diabetes Center, New York, NY
Yale University, New Haven, CT
- The safety and scientific validity of a research study is the responsibility of the study investigators and the study sponsor.
- It is important to evaluate the risks and potential benefits of clinical studies and to talk to your health care provider(s) before participating in a study.